Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb;597(4):1121-1141.
doi: 10.1113/JP275856. Epub 2018 Sep 12.

Pulmonary vascular dysfunction in metabolic syndrome

Conor Willson  1 , Makiko Watanabe  1 , Atsumi Tsuji-Hosokawa  1 , Ayako Makino  1
Affiliations
Review

Pulmonary vascular dysfunction in metabolic syndrome

Conor Willson et al. J Physiol. 2019 Feb.

Abstract

Metabolic syndrome is a critically important precursor to the onset of many diseases, such as cardiovascular disease, and cardiovascular disease is the leading cause of death worldwide. The primary risk factors of metabolic syndrome include hyperglycaemia, abdominal obesity, dyslipidaemia, and high blood pressure. It has been well documented that metabolic syndrome alters vascular endothelial and smooth muscle cell functions in the heart, brain, kidney and peripheral vessels. However, there is less information available regarding how metabolic syndrome can affect pulmonary vascular function and ultimately increase an individual's risk of developing various pulmonary vascular diseases, such as pulmonary hypertension. Here, we review in detail how metabolic syndrome affects pulmonary vascular function.

Keywords: Diabetes; Insulin resistance; dyslipidemia; obesity; pulmonary artery; pulmonary hypertension.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abernethy AD, Stackhouse K, Hart S, Devendra G, Bashore TM, Dweik R & Krasuski RA (2015). Impact of diabetes in patients with pulmonary hypertension. Pulm Circ 5, 117–123. - PMC - PubMed
    1. Achari AE & Jain SK (2017). Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int J Mol Sci 18, 1321. - PMC - PubMed
    1. Agard C, Rolli‐Derkinderen M, Dumas‐de‐La‐Roque E, Rio M, Sagan C, Savineau JP, Loirand G & Pacaud P (2009). Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension. Br J Pharmacol 158, 1285–1294. - PMC - PubMed
    1. Agarwal M, Agrawal S, Garg L & Lavie CJ (2017). Relation between obesity and survival in patients hospitalized for pulmonary arterial hypertension (from a Nationwide Inpatient Sample Database 2003 to 2011). Am J Cardiol 120, 489–493. - PubMed
    1. Ahren B, Mansson S, Gingerich RL & Havel PJ (1997). Regulation of plasma leptin in mice: influence of age, high‐fat diet, and fasting. Am J Physiol Regul Integr Comp Physiol 273, R113–R120. - PubMed

Publication types

MeSH terms

LinkOut - more resources